Abstract:Abstract Background Metastatic bone disease is a frequent complication of advanced non-small-cell lung cancer and causes skeletal-related events which result in a poor prognosis. A standard method to assess the therapeutic response of bone metastases does not currently exist. We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine–cisplatin plus rh-endostatinfor previously untreated non-small cell lung cancer with bone metastases. Methods We did a phase 4, randomised, prospective, double-blind, placebo-controlled clinical trial in Shanghai Sixth Peopleu0027s Hospital, Shanghai, China. Inclusion criteria were non-small-cell lung cancer patients with bone metastases confirmed by pathology or cytology; available imaging data of pelvic metastatic lesions; aged 18 to 75 years old; expected survival at least 3 months; not receiving taxane, bevacizumab, thalidomide, rh-endostatin, or bisphosphonate; not having radiation therapy within 3 months of enrollment into study; normal results of routine blood tests, liver and kidney function, and electrocardiogram; absence of cardiovascular disease, autoimmune disease, vasculitis, severe infection, diabetes, and other concomitant disease; and signed informed consent. Exclusion criteria were receiving granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor during chemotherapy, intolerance to adverse reaction, and allergy to contrast agents. Patients were randomly assigned to treatment group and control group at a ratio of 2:1 by random code generation by an independent biostatistician in a double-blind fashion. Participants received either vinorelbine–cisplatin plus rh-endostatin or vinorelbine–cisplatin plus placebo. Vinorelbine (25 mg/m 2 ) and cisplatin (75 mg/m 2 ) were administered intravenously on the first day of a 21 day cycle. Patients received rh-endostatin (7·5 mg/m 2 ) or placebo on days 1–14 of a cycle. The primary end points were objective response rate (complete remission+partial remission)/total × 100) and disease control rate (complete remission+partial remission+stable disease)/total × 100). Measurements including K trans , K ep , and V e were evaluated by dynamic contrast-enhanced MRI before treatment and after completion of 2 treatment cycles. Blood concentrations of bone metabolites, tumour markers, and tumour vascular growth related factors were measured before and after treatment. Comparisons were made using paired t-test. Kaplan-Meier survival analysis was used to indicate the correlation between some measurements and progression-free survival or overall survival. The difference in K trans between patients who had partial remission or stable disease group and those who had disease progression was tested using the Chi-square test. All statistical analyses were performed with SPSS version 21.0. This trial was approved by the State Food and Drug Administration (No: S20050088) and China State Food and Drug Administration. The trial is registered with China Clinical Trials Registry, number chictr-ctr-09000569. Written informed consent and ethical approval was obtained. Findings We enrolled 33 patients (aged 52–70, 15 men and 18 women) of whom 28 were evaluable (20 in treatment group and 8 in control group). Five patients were excluded: 2 patients in treatment group and 1 patient in control group used granulocyte-macrophage colony stimulating factor, and 2 patients in the control group refused treatment. Objective response rate was higher (30% vs 0%; p Interpretation Addition of rh-endostatin to treatment with vinorelbine–cisplatin increased the treatment response in patients with non-small cell lung cancer and bone metastases. Quantitative analysis using dynamic contrast-enhanced MRI can be used to evaluate therapeutic response and to predict survival of bone metastases after anti-angiogenesis therapy. Limitations of this study include the small number of patients and the single-centre design. Funding National Natural Science Foundation of China [grant number 81201628].

Usefulness of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Treatment Response to Vinorelbine-Cisplatin with or Without Recombinant Human Endostatin in Bone Metastasis of Non-Small Cell Lung Cancer

Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial

Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diag-nosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF

Whole-tumor Perfusion CT Using Texture Analysis in Unresectable Stage IIIA/B Non-Small Cell Lung Cancer Treated with Recombinant Human Endostatin.

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

Quantitative Analysis of Pre-Treatment Dynamic Contrast-Enhanced Ultrasound for Assessing the Response of Colorectal Liver Metastases to Chemotherapy Plus Targeted Therapy: a Dual-Institutional Study.

Abstract 2252: Correlation of Baseline Value of Folate Receptor-Positive Circulating Tumor Cells and Efficacy of Pemetrexed and Dynamic Monitoring Study in Non-Small Cell Lung Cancer Patients Receiving First-Line Platinum-Based Chemotherapy

Early Assessment of Response to Chemotherapy in Lung Cancer Using Dynamic Contrast-Enhanced MRI: a Proof-of-concept Study

[Role of Magnetic Resonance Imaging for Response Evaluation and Predictive Value of Tumor Biomarkers in the Neoadjuvant Chemotherapy for Breast Cancer:A Multi-Center Prospective Study].

The Role of Dynamic Contrast-enhanced MRI for Evaluating Therapeutic Effect for NSCLC Patients with Chemotherapy or Chemoradiotherapy

Circulating endothelial cells and tumor blood volume as predictors in lung cancer.

Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer

Efficacy and safety of recombinant human endostatin combined with whole-brain radiotherapy in patients with brain metastases from NSCLC.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging For Prediction Of Response To Neoadjuvant Chemotherapy In Breast Cancer

Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer

Efficacy of Endostar Combined with Vinorelbine and Cisplatin in Treatment of Advanced Non-Small-cell Lung Cancer

Effects of Combining Immune Checkpoint Inhibitors and Anti-Angiogenic Agents on Bone Metastasis in Non-Small Cell Lung Cancer Patients.

Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study

Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer

Evaluating the Treatment Efficacy of Nano-Drug in a Lung Cancer Model Using Advanced Functional Magnetic Resonance Imaging